MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
1.560
-0.050
-3.11%
After Hours: 1.590 +0.03 +1.92% 19:45 02/23 EST
OPEN
1.590
PREV CLOSE
1.610
HIGH
1.640
LOW
1.540
VOLUME
763.35K
TURNOVER
--
52 WEEK HIGH
4.855
52 WEEK LOW
1.480
MARKET CAP
105.08M
P/E (TTM)
-1.9559
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRDF last week (0216-0220)?
Weekly Report · 20h ago
Cardiff Oncology to Present at Oppenheimer Annual Healthcare Life Sciences Conference
Reuters · 4d ago
Weekly Report: what happened at CRDF last week (0209-0213)?
Weekly Report · 02/16 10:24
Cardiff Oncology Inc. Files Initial Statement of Beneficial Ownership for Chief Accounting Officer Brigitte Lindsay
Reuters · 02/09 21:00
Weekly Report: what happened at CRDF last week (0202-0206)?
Weekly Report · 02/09 10:25
VOO vs. VTI vs. VTWO: Which Vanguard ETF Offers the Best Upside in 2026?
TipRanks · 02/06 12:57
Weekly Report: what happened at CRDF last week (0126-0130)?
Weekly Report · 02/02 10:25
Cardiff Oncology Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 01/28 17:27
More
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Webull offers Cardiff Oncology Inc stock information, including NASDAQ: CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.